Biovica International – Positive Results With DiviTum® From New Pfizer Study Presented at the AACR Congress
- Tuesday, April 17, 2018, 1:45
- PR Newswire
- Add a comment
UPPSALA, Sweden, April 17, 2018 /PRNewswire/ —
New results from a Pfizer study on Ibrance® (palbociclib, Pfizer) of women with metastatic breast cancer demonstrate that DiviTum can provide fast evaluation of biologic effect demonstrating CDK 4/6 inhibition.
The study, presented…
Source: https://www.prnewswire.com/news-releases/biovica-international—positive-results-with-divitum-from-new-pfizer-study-presented-at-the-aacr-congress-300631000.html
About the Author
admin has written 20655 stories on this site.